Bone News and Research

RSS

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE (bortezomib) for Injection, which updates the label to include additional long-term overall survival (OS) data from the VISTA trial.

2 Nov 2011

First Edition: November 1, 2011

Today's headlines include a report that the health law's early retirees' health insurance fund may be running out.

1 Nov 2011

National lupus organizations urge NICE to recommend Benlysta for coverage

National lupus organizations in more than 28 countries, and individuals with lupus and their families around the world, are rallying to protect access to new treatments and the development of future therapies to treat lupus.

1 Nov 2011

European Congress on Osteoporosis & Osteoarthritis to be held March 21-24

The International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) have worked in partnership to develop a unique springtime meeting programme for healthcare professionals, researchers and young scientists. With over 5,500 participants, this has become the largest educational event and most vibrant clinical research forum for osteoporosis and osteoarthritis in Europe.

1 Nov 2011

'Heroes of Hope Race for Brain Tumor Research' event to be held on Nov. 6

Veronica Cappalonga, 28, knows a lot about living with cancer. Diagnosed at age 6 with leukemia and at 22 with a malignant brain tumor, the Los Angeles (Mar Vista area) resident will walk in the Nov. 6 Heroes of Hope Race for Brain Tumor Research - not only to help fundraise, but also to show that survivors can fight these diseases with dignity.

29 Oct 2011

Researchers uncover biochemical signals that trigger generation of new lung alveoli

Researchers at Weill Cornell Medical College say they have taken an important step forward in their quest to "turn on" lung regeneration -- an advance that could effectively treat millions of people suffering from respiratory disorders.

29 Oct 2011

ZIOPHARM reports promising preclinical data with palifosfamide in pediatric sarcoma model

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced the presentation of promising preclinical data with palifosfamide in a pediatric sarcoma model.

29 Oct 2011

Merck third quarter global sales increase 8% to $12.0 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2011.

29 Oct 2011

BZL and ATLAB Pharma partner to develop 177Lu-J591 for metastatic prostate cancer treatment

ATLAB Pharma SAS and BZL Biologics LLC have entered into a sublicense agreement to develop 177Lu-J591 for cancer treatment. It includes exclusive rights to manufacture, develop and commercialize this radiopharmaceutical product worldwide as well as a joint Phase IIB/III clinical validation program.

29 Oct 2011

EC approves Lilly's ALIMTA as continuation maintenance therapy for NSCLC

Eli Lilly and Company announced today that the European Commission has granted approval for the use of ALIMTA (pemetrexed for injection) as a single agent for continuation maintenance therapy in patients with a particular type of lung cancer, called advanced nonsquamous non-small cell lung cancer

29 Oct 2011

Spinal USA to introduce two new solutions at NASS meeting

Spinal USA, LLC announced today that it will introduce two new additions to the company's portfolio of spinal treatment solutions at this year's meeting of the North American Spine Society (NASS) in Chicago, IL, November 1-5.

29 Oct 2011

Scientists challenge theory about why chemotherapy agents target cancer

Challenging a half-century-old theory about why chemotherapy agents target cancer, scientists at Dana-Farber Cancer Institute have devised a test that can predict how effective the drugs will be by determining whether a patient's tumor cells are already "primed" for death.

28 Oct 2011

Platform approach to chemically incorporate homing receptors onto surface of cells

Stem cell therapies hold enormous potential to address some of the most tragic illnesses, diseases, and tissue defects world-wide. However, the inability to target cells to tissues of interest poses a significant barrier to effective cell therapy.

28 Oct 2011

ORBIT 3D X-ray scanner can be integrated into operations

Having an operation always places strain on patients, and this is especially true of complicated operations. Surgeons use 3D X-rays to check the results before the patient has left the operating room. This does help to avoid possible complications, but it also means interrupting the surgery. Fraunhofer researchers are now developing a 3D X-ray system that can be integrated seamlessly into operating procedure - with no more forced interruptions.

28 Oct 2011

Manipulating normal bacteria could tackle gum disease

Normal bacteria which live in our mouths provide the catalyst for the development of gum disease, a debilitating condition which leads to painful gums and the loosening of teeth, new research from Queen Mary, University of London has found.

28 Oct 2011

Regeneron announces positive results from sarilumab Phase 2b trial on RA

Regeneron Pharmaceuticals, Inc. today announced that detailed clinical data from the positive Phase 2b portion of the seamless Phase 2/3 MOBILITY trial of sarilumab in rheumatoid arthritis (RA) will be presented at a late-breaking poster session at the upcoming American College of Rheumatology (ACR) Annual Scientific Meeting, which will take place from November 5-9 in Chicago.

28 Oct 2011

Novel scarless surgery effectively removes skull base tumors

A technique developed by Johns Hopkins surgeons is providing a new route to get to and remove tumors buried at the base of the skull: through the natural hole behind the molars, above the jawbone and beneath the cheekbone.

27 Oct 2011

HDM and SCT increase overall survival for patients with AL amyloidosis

A team of researchers led by Boston University School of Medicine (BUSM), has found treatment of selected immunoglobulin light chain (AL) amyloidosis patients with high-dose melphalan and autologous stem cell transplantation (HDM/SCT) resulted in a high organ response rate and increased overall survival (OS), even for those patients who did not achieve a hematologic complete response.

27 Oct 2011

New potential leukemia therapy targets and kills cancer cells

A new potential leukemia therapy targets only cancer cells, while leaving healthy cells alone. Many current chemotherapy treatments affect cancer cells and healthy cells, causing significant side effects, such as fatigue, hair loss, nausea, anxiety and depression.

27 Oct 2011

Bacterin reports results of two-year study for OsteoSponge

Bacterin International Holdings, Inc., a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, reported results of a two-year study for OsteoSponge.

27 Oct 2011